Literature DB >> 20175190

Paroxetine exposure during pregnancy and cardiac malformations.

Anthony R Scialli1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20175190     DOI: 10.1002/bdra.20655

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


× No keyword cloud information.
  5 in total

Review 1.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

2.  Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study.

Authors:  Anthony Wemakor; Karen Casson; Ester Garne; Marian Bakker; Marie-Claude Addor; Larraitz Arriola; Miriam Gatt; Babak Khoshnood; Kari Klungsoyr; Vera Nelen; Mary O'Mahoney; Anna Pierini; Anke Rissmann; David Tucker; Breidge Boyle; Lolkje de Jong-van den Berg; Helen Dolk
Journal:  Eur J Epidemiol       Date:  2015-07-07       Impact factor: 8.082

3.  Identifying associations between maternal medication use and birth defects using a case-population approach: an exploratory study on signal detection.

Authors:  Linda de Jonge; Priscilla A Zetstra-van der Woude; H Jens Bos; Lolkje T W de Jong-van den Berg; Marian K Bakker
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.606

4.  Paroxetine use in pregnancy and increased risk of heart defects: Evaluating the evidence.

Authors:  Adrienne Einarson
Journal:  Can Fam Physician       Date:  2010-08       Impact factor: 3.275

5.  Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat?

Authors:  Orna Diav-Citrin; Asher Ornoy
Journal:  Obstet Gynecol Int       Date:  2011-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.